GlassScriptPhysician profile
Susan Debey
NPI 1619281680
$11,122.50
in general payments reported to CMS, 2019-2025
32 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,861 · 2022: $2,234 · 2023: $2,146 · 2024: $2,668 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,980 · Education: $47.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,979.88 |
| Education | $47.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,250.06 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,992.85 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $788.33 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $683.72 | 2021-2025 | Stelara, Tremfya, Simponi |
| Intercept Pharmaceuticals, INC. | $509.23 | 2021-2024 | Ocaliva |
| Pfizer INC. | $410.54 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $340.52 | 2021-2025 | Linzess |
| Merck Sharp & Dohme LLC | $311.02 | 2021-2024 | Dificid, Zinplava |
| Evoke Pharma, INC. | $297.07 | 2021-2025 | Gimoti |
| Celgene Corporation | $258.81 | 2021-2024 | Zeposia |
| Genzyme Corporation | $247.51 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $222.29 | 2022-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $195.44 | 2021-2023 | |
| Vivus LLC | $157.30 | 2021-2022 | |
| Lilly USA, LLC | $152.56 | 2023-2025 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $135.26 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $134.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $126.94 | 2023-2024 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $126.14 | 2021-2025 | Injectafer |
| Gilead Sciences, INC. | $117.32 | 2021-2025 | |
| Organon LLC | $108.81 | 2023-2024 | Hadlima, Renflexis |
| Janssen Scientific Affairs, LLC | $101.11 | 2021 | |
| Phathom Pharmaceuticals, INC. | $100.34 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $81.65 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $63.70 | 2021 | |
| Fresenius Kabi USA, LLC | $48.23 | 2023 | |
| Braintree Laboratories, INC. | $45.17 | 2021-2023 | Sutab |
| Ferring Pharmaceuticals INC. | $36.85 | 2022-2024 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $29.93 | 2025 | Iqirvo |
| Boston Scientific Corporation | $19.46 | 2023 | Resolution 360 Clip |
| Endogastric Solutions, INC | $18.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Debey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.